Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPOP-R versus CHOP-R in previously untreated diffuse large B-cell lymphoma
2005-001100-40Phase 2Completed
- Sponsor
- CTI BioPharma
- Start
- Nov 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of pixantrone in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by CTI BioPharma. Primary endpoint: Complete objective response rate (CR + CRu). Started Nov 2005; status: completed.
02
Drugs
pixantrone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2005-001100-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001100-40.